These are the headlines you Need2Know:
* **Tamer Hurricane Season Expected:**
The 2018 hurricane season is shaping up to be "below-normal.” Experts with NOAA now predict nine to 13 named storms ー maybe only two major hurricanes of Category 3 strength or higher. Last year there were 17 named storms, and three major hurricanes hit U.S. soil. For more on the condition of the storm, [click here](https://www.cnn.com/2018/08/09/us/noaa-hurricane-season-forecast-wxc/index.html).
* **Space Forces Needs a Logo and a Release Date:**
Vice President Mike Pence says the Pentagon is working to create Space Force, a sixth armed service to beef up military capabilities in space and help protect satellites. The biggest rivals in space are China and Russia. Congress needs to authorize and fund the force. Vote on the logo [here](https://arstechnica.com/tech-policy/2018/08/trump-wants-campaign-donors-to-vote-on-the-logo-for-the-space-force/), and read more [here](https://www.nytimes.com/2018/08/09/us/politics/trump-pence-space-force.html).
* **New NFL Season, More Protests:**
Several players took a knee, raised their fists or stayed off the field during the national anthem at last night’s preseason games. The NFL recently announced a policy that all players must stand for the national anthem, or remain in the locker room without penalty. But that policy is currently on hold. For more on this story, [click here](https://www.nbcnews.com/news/us-news/some-nfl-players-kneel-or-raise-fists-during-anthem-preseason-n899481).
* **A Potential 2020 Run for Stormy Daniels's Lawyer:**
Michael Avenatti, the lawyer for the adult entertainment start Stephanie Clifford, also known as Stormy Daniels, said he might run for president. Known as one of President Trump’s most outspoken critics in his capacity as Clifford's lawyer, Avenatti has also discussed his interest in challenging Trump on policies such as immigration. For more, check out [POLITICO](https://www.politico.com/story/2018/08/10/michael-avenatti-presidential-run-iowa-2020-771291).
Cheddar's Jill Wagner gets into the latest.
Subscribe to the Need2Know newsletter [here](https://theneed2know.com).
Healthcare workforce management platform ShiftMed
recently announced a $45 million funding round.
The company's platform connects nurses and healthcare professionals to hospitals and other healthcare providers.
ShiftMed's new funding comes amid widespread labor shortages in the healthcare sector. The company's CEO Todd Walrath joins Cheddar News' Closing Bell to discuss.
Universities like UCLA, Yale, and Duke have announced they're implementing remote learning amid the COVID omicron variant surge, despite President Biden recommending that K-12 schools should continue in-person education. Jared C. Bass, senior director for Higher Education at American Progress, joined Cheddar to break down what institutions of higher education might be considering differently. "I think some universities are allowing periods of a bit of a respite to allow students to get testing and make sure when they do return back to campus that they're healthy," he noted.
Supply chain issues have become one of the biggest roadblocks for the U.S. EV market, with production woes likely to stunt the industry's growth in 2022. Rich Steinberg, electric vehicle expert and industry advisor, told Cheddar that the Biden administration investing in domestic mining for essential minerals used in battery manufacturing — such as lithium — could help alleviate the bottlenecks. "Some of those same materials are available domestically, they just haven't been prioritized," he said, noting the paradox between green tech and "dirty" mining. "The good news is that there are ways to extract those materials cleanly."
Hyperfine, the pioneer of the very first FDA-approved portable MRI device, made its public debut on the Nasdaq via a SPAC merger. CEO Dave Scott joined Cheddar's "Opening Bell" to discuss the IPO launch, the company's valuation at $580 million, and the impact of its machine called Swoop. "We can roll an MRI system, our MRI Swoop system, right into the room where you are, right up to your patient bedside, and scan you right there and get an image in less than an hour," he explained.
Dr. Rob Davidson, Executive Director of the Committee to Protect Health Care and an ER Physician in West Michigan, joins Cheddar News to break down the expectations of Pfizer's new COVID-19 treatment pill.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
